ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.

2.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

Advanz Pharma has received 53.75% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Advanz Pharma and other stocks. Vote “Outperform” if you believe CXRXF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CXRXF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Miscellaneous

Receive CXRXF News and Ratings via Email

Sign-up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter.

Advanz Pharma (OTCMKTS:CXRXF) Frequently Asked Questions

How has Advanz Pharma's stock been impacted by COVID-19 (Coronavirus)?

Advanz Pharma's stock was trading at $3.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CXRXF stock has decreased by 3.9% and is now trading at $3.45. View which stocks have been most impacted by Coronavirus.

When is Advanz Pharma's next earnings date?

How were Advanz Pharma's earnings last quarter?

Advanz Pharma Corp (OTCMKTS:CXRXF) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter. The business earned $129.99 million during the quarter. Advanz Pharma had a negative return on equity of 66.95% and a negative net margin of 39.13%. View Advanz Pharma's earnings history.

Has Advanz Pharma been receiving favorable news coverage?

Headlines about CXRXF stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Advanz Pharma earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAdvanz Pharma.

What is Advanz Pharma's stock symbol?

Advanz Pharma trades on the OTCMKTS under the ticker symbol "CXRXF."

How do I buy shares of Advanz Pharma?

Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advanz Pharma's stock price today?

One share of CXRXF stock can currently be purchased for approximately $3.45.

How big of a company is Advanz Pharma?

Advanz Pharma has a market capitalization of $168.74 million and generates $508.32 million in revenue each year. Advanz Pharma employs 435 workers across the globe.